Implementing Primaquine Single Low Dose in Africa

Fact Sheet

Project Information

**IMPRIMA**
Grant agreement ID: 101103213

**DOl**
10.3030/101103213

<table>
<thead>
<tr>
<th>Start date</th>
<th>End date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 April 2023</td>
<td>31 March 2027</td>
</tr>
</tbody>
</table>

Funded under
Health

**Total cost**
€ 3 969 906,25

**EU contribution**
€ 3 967 406,25

Coordinated by
UNIVERSITE DE STRASBOURG
France

Objective

The 2021 World Malaria Report estimates that the number of clinical cases in 2020 was 241 million and the number of deaths was 627,000, an increase of 69,000 compared to 2019, a timely reminder to maintain good malaria control and introduce novel elimination strategies. In 2012, to further reduce malaria transmission and possibly reach elimination, the WHO recommended adding single low dose primaquine (SLDPQ) to artemisinin based treatments (ACTs) in low transmission settings and more recently in areas where artemisinin resistance is emerging. SLDPQ kills mature gametocytes, blocking the transmission between humans and mosquitoes and should see a reduction in the malaria burden with widespread deployment. Compounding the poor uptake of SLDPQ is the lack of child-friendly formulations of primaquine and lingering anxieties regarding primaquine-related acute haemolysis in patients with glucose-6-phosphate dehydrogenase deficiency.
Building on the good progress of the ‘Developing Paediatric Primaquine’ EDCTP2-funded project, aiming at prequalifying paediatric formulations, we have conceived the IMPRIMA project to support the adoption of SLDPQ by conducting a real-life implementation study using our flavoured primaquine for children. Key to our success is the unique triangle of interconnecting activities - clinical, community/sociological, and policy - all within a matrix of capacity building and strong coordination by all seven partners.

Our ambitious proposal aims to demonstrate the safety, acceptability, and community benefit of SLDPQ in 3 African countries with different malaria epidemiologies. Engagement with the communities and policy makers are fundamental to effect a positive change in drug policy and contribute to malaria elimination. In parallel, capacity will be enhanced for conducting clinical trials and monitoring the evolution of antimalarial drugs resistance. We believe the IMPRIMA project fits extremely well with the priorities of this call.

**Fields of science**

- medical and health sciences > health sciences > infectious diseases > malaria
- medical and health sciences > health sciences > public health > epidemiology
- medical and health sciences > basic medicine > pharmacology and pharmacy > drug resistance
- medical and health sciences > clinical medicine > paediatrics
- natural sciences > biological sciences > zoology > invertebrate zoology

**Keywords**

- malaria
- primaquine
- Africa
- Implementation
- transmission blocking

**Programme(s)**

HORIZON.2.1 - Health

**Topic(s)**

HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01 - Promoting implementation of research results into policy and practice
Call for proposal

HORIZON-JU-GH-EDCTP3-2022-01

See other projects for this call

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Coordinator

UNIVERSITE DE STRASBOURG

Net EU contribution
€ 794 127,50

Address

Rue blaise pascal 4
67081 Strasbourg
France

Region

Grand Est > Alsace > Bas-Rhin

Activity type

Higher or Secondary Education Establishments

Links

Contact the organisation
Website
Participation in EU R&I programmes
HORIZON collaboration network

Other funding
€ 0,00

Participants (6)

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom

Net EU contribution

€ 427 622,50

Address
Wellington square university offices
OX1 2JD Oxford

Region
South East (England) > Berkshire, Buckinghamshire and Oxfordshire > Oxfordshire

Activity type
Higher or Secondary Education Establishments

Links
Contact the organisation
Website
Participation in EU R&I programmes
HORIZON collaboration network

Other funding
€ 0,00

---

RESEAU MEDICAMENTS ET DEVELOPPEMENT

France

Net EU contribution

€ 479 490,00

Address
21b avenue du commandant l'herminier
44600 Saint nazaire

Region
Pays de la Loire > Pays de la Loire > Loire-Atlantique

Activity type
Other

Links
Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network

Other funding
€ 2 500,00
GROUPE DE RECHERCHE ACTION EN SANTE SARL
Burkina Faso
Net EU contribution
€ 835 756,25
Address
Secteur 25 somgande rue 25 26 porte 79
06 Ouagadougou
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network
Other funding
€ 0,00

CENTRE NATIONAL D'APPLICATION DE RECHERCHES PHARMACEUTIQUES
Madagascar
Net EU contribution
€ 569 375,00
Address
Rue rp rahajarizafy
101 Antananarivo
Activity type
Higher or Secondary Education Establishments
Links
Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network
Other funding
€ 0,00
INSTITUT NATIONAL DE SANTE PUBLIQUE
Burundi
Net EU contribution
€ 609 267,50
Address
Avenue de l'hôpital 3
Bujumbura  🇧🇮
Activity type
Higher or Secondary Education Establishments
Links
Contact the organisation  
Participation in EU R&I programmes  
HORIZON collaboration network  
Other funding
€ 0,00

UNIVERSITEIT LEIDEN
Netherlands
Net EU contribution
€ 251 767,50
Address
Rapenburg 70
2311 EZ Leiden  🇳🇱
Region
West-Nederland > Zuid-Holland > Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Links
Contact the organisation  Website  
Participation in EU R&I programmes  
HORIZON collaboration network  
Other funding
€ 0,00

EC signature date 21 March 2023
Last update: 14 July 2023